Antibody therapy
Alemtuzumab
ALLO-647
Daratumumab
Mogamulizumab
Obinutuzumab
Ofatumumab
Rituximab
Tafasitamab
Ublituximab
Ulocuplumab
BCL-2 inhibitors
Navitoclax
Venetoclax
Bispecific antibodies
Blinatumomab
Glofitamab
Mosunetuzumab
REGN1979
CAR T-cell therapy
ADI-001
ALLO-501
Axicabtagene ciloleucel
JCAR014
KTE-X19
Lisocabtagene maraleucel
MB-CART2019.1
Tisagenlecleucel
Cellular therapy
Allo-CBT
Allo-HSCT
Allo-NKT
Auto-HSCT
DLI
Checkpoint inhibitors
Atezolizumab
Avelumab
Durvalumab
Geptanolimab
Ipilimumab
Nivolumab
Pembrolizumab
Sintilimab
Chemokine receptor antagonists
Plerixafor
Chemotherapy
Bendamustine
Bleomycin
Busulfan
Carmustine
Chlorambucil
CHOP
Cyclophosphamide
Cytarabine
Dacarbazine
DHAP
Doxorubicin
EPOCH
Etoposide
Fludarabine
Gemcitabine
Melphalan
Methotrexate
Mitoxantrone
Pentostatin
Pralatrexate
Temozolomide
Vinblastine
Conjugated antibodies
(177)Lu lilotomab satetraxetan
Brentuximab vedotin
Camidanlumab tesirine
Ibritumomab tiuxetan
Inotuzumab ozogamicin
Loncastuximab tesirine
Pinatuzumab vedotin
Polatuzumab vedotin
TRPH-222
VLS-101
Histone modifiers
Abexinostat
Belinostat
Panobinostat
Romidepsin
Tazemetostat
Tucidinostat
Vorinostat
Hypomethylating agents
Azacitidine
Immune modulators
Avadomide
Interferon alfa-2a
Lenalidomide
NT-17
Kinase inhibitors
Acalabrutinib
Alisertib
Copanlisib
Duvelisib
Entospletinib
Ibrutinib
Idelalisib
Itacitinib
LOXO-305
ME-401
Palbociclib
Parsaclisib
Umbralisib
Zanubrutinib
Micro RNAs
Cobomarsen
mTOR inhibitors
Everolimus
Temsirolimus
Multi-cytokine inhibitors
BNZ-1
Nuclear export inhibitors
Selinexor
Nuclear receptor agonists
Bexarotene
Dexamethasone
Methylprednisolone
Prednisone
Phospholipid-drug conjugates
CLR 131
Pro-apoptotic molecules
Tolinapant
Proteasome inhibitors
Bortezomib
Carfilzomib
Ixazomib